Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors

Satoshi Yoshiba,Mendel Jansen,Nobuko Matsushima,Shuquan Chen,Jeanne Mendell

Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors

2016

Satoshi Yoshiba
Mendel Jansen
Nobuko Matsushima
Shuquan Chen
Jeanne Mendell

Purpose The purpose of this analysis was to develop a population pharmacokinetic (PK) model for patritumab, a fully human monoclonal antibody that targets human epidermal growth factor receptor 3.

Keywords:

Human epidermal growth factor
non-small cell lung cancer (NSCLC)
Patritumab
Pharmacology
Monoclonal antibody
Oncology
Receptor
Population
Medicine
Internal medicine
Pharmacokinetics
human epidermal growth factor receptor
population pharmacokinetics
pharmacokinetic analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations